Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.

ABSTRACT: Hepatocellular carcinoma (HCC) has one of highest mortalities globally amongst cancers, but has limited therapeutic options once in the advanced stage. Hepatitis B or C virus infection are the most common drivers for HCC carcinogenesis, triggering chronic liver inflammation and adding to the complexity of the immune microecosystem of HCC. The emergence of immunotherapy has afforded a new avenue of therapeutic options for patients with advanced HCC with a history of hepatitis B or C virus infection. This article reviews the change of immunity elicited by hepatitis B or C virus infection, the immune feature of HCC, and the clinical evidence for immunotherapy in advanced HCC and discusses future directions in this field.

SUBMITTER: Bonilla CM 

PROVIDER: S-EPMC7597818 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature